Statistics

Total Visits

Views
Long-Term Survivors with EGFR Wild-Type Advanced NSCLC Treated with Second-Line Erlotinib: Subgroup Analysis from WILT Study47

Select a period of time:

Number of views in the range

Views
Long-Term Survivors with EGFR Wild-Type Advanced NSCLC Treated with Second-Line Erlotinib: Subgroup Analysis from WILT Study11

Views

Views
December 20252
January 20260
February 20260
March 20262
April 20263
May 20261
June 20263
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States3
Bolivia1
Canada1
Germany1
Iran1
Mexico1
Singapore1
Turkey1
South Africa1
 

Top cities views

Views
Ashburn1
Cochabamba1
Durban1
Frankfurt am Main1
Hamilton1
Istanbul1
Mexico City1
Santa Clara1